SmartMed Technologies to test Cladribine as treatment for Multiple Sclerosis relapses
08/28/2020

SmartMed Technologies today announced that it is researching and testing cladribine as a potential treatment for patients who relapse from Multiple Sclerosis.

Online PR News – 28-August-2020 – YEONGDEUNGPO-GU – SmartMed Technologies’ Medical team have researched cladribine over the last few years as a short-course of treatment and oral therapy which is thought to selectively target lymphocytes, which could be integral to the pathological process of relapsing multiple sclerosis.

SmartMed Technologies’ Chief Medical Officer, Dr. Norman Hammond commented on the research saying "We are actively monitoring different processes and delighted with the effort we have made so far. Cladribine tablets could be the answer as a new treatment paradigm for relapsing multiple sclerosis and we look forward to carrying out more tests to come to a final conclusion."

"What we have found out is that a majority of multiple sclerosis therapies require a continued and regular dose of medication. An oral treatment approach consisting of short and infrequent cycles may help lower the treatment burden for patients and based on our clinical research in recent years, we have gained more knowledge for the treatment course of cladribine and we hope to announce a breakthrough very soon," added Dr. Norman Hammond, Chief Medical Officer of SmartMed Technologies.

About Us - SmartMed Technologies

SmartMed Technologies is a pioneering bioinformatics medical research and development company focused on delivering innovative medical products through artificial intelligence technology to combat prevalent, rare and emerging diseases.

Based in Seoul, our team collects and analyzes big data, utilizing artificial intelligence to gain insight into complex diseases such as leukemia and different cancers. Our approach centers on genome integration with high-performance computers and deep artificial intelligence learning.

With our advanced technology, we have been able to cut costs arising from industry trial-and-error procedures; with the integration of supercomputers into our work, we are able to run more comprehensive simulations, better target proteins, discover new drug compounds for a multitude of diseases, and generally increase our capacity for successful drug development.

With international recognition for our research and projects, some in collaboration with world-renowned institutions, we consistently aim to develop our understanding in the medical field through artificial intelligence and advanced clinical trials.